---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-066006"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2026-10-15T20:26:10+00:00"
generated_at: "2026-10-15T20:27:12.608383+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Crescent Biopharma updates pipeline: CR-001 ASCEND combo cohorts enrolling; CR-002 IND cleared

## Summary
- ASCEND Phase 1/2 trial of CR-001 (PD-1 x VEGF bispecific) completed monotherapy dose escalation; initial data expected Q1 2027, including ORR in up to 12 1L NSCLC patients and data from >125 patients.
- Chemo combo expansion cohorts enrolling in ASCEND; initial data mid-2027 across 1L NSCLC, 1L pMMR/MSS CRC, 3L CRC, 1L biliary, 1L pMMR endometrial, and gastric/GEJ cancers.
- Partner Kelun-Biotech runs China trials of CR-001 (SKB118) plus TROP2 ADC sac-TMT: Phase 2 NSCLC data mid-2027; Phase 2 EGFR-mutant NSCLC initiating; Phase 1/2 with CR-003 (SKB105) to start H1 2027.
- CR-002 (PD-L1 topoisomerase inhibitor ADC) received FDA IND allowance in Oct 2026; global Phase 1/2 APOLLO trial to start Q4 2026 in advanced solid tumors, initial data H2 2027.
- Kelun-Biotech granted Crescent exclusive rights to CR-003 (SKB105), an integrin-beta 6 ADC, for US, Europe and markets outside Greater China; China Phase 1/2 proof-of-concept data expected Q1 2027.

## SEC filing metadata
- accession: 0001628280-26-066006
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2026-10-15T20:26:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/0001628280-26-066006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-066006
- JSON: https://secwatch.observer/filing/0001628280-26-066006.json
- Plain text: https://secwatch.observer/filing/0001628280-26-066006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.